158 related articles for article (PubMed ID: 1483923)
1. Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.
Yana I; Nakamura T; Shin E; Karakawa K; Kurahashi H; Kurita Y; Kobayashi T; Mori T; Nishisho I; Takai S
Jpn J Cancer Res; 1992 Nov; 83(11):1113-6. PubMed ID: 1483923
[TBL] [Abstract][Full Text] [Related]
2. Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas.
Herfarth KK; Wick MR; Marshall HN; Gartner E; Lum S; Moley JF
Genes Chromosomes Cancer; 1997 Sep; 20(1):24-9. PubMed ID: 9290950
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas.
Khosla S; Patel VM; Hay ID; Schaid DJ; Grant CS; van Heerden JA; Thibodeau SN
J Clin Invest; 1991 May; 87(5):1691-9. PubMed ID: 2022740
[TBL] [Abstract][Full Text] [Related]
5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
6. Loss of genes on chromosome 22 in medullary thyroid carcinoma and pheochromocytoma.
Takai S; Tateishi H; Nishisho I; Miki T; Motomura K; Miyauchi A; Kato M; Ikeuchi T; Yamamoto K; Okazaki M
Jpn J Cancer Res; 1987 Sep; 78(9):894-8. PubMed ID: 2889715
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the p53 gene in human functional adrenal neoplasms.
Lin SR; Lee YJ; Tsai JH
J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas.
Petri BJ; Speel EJ; Korpershoek E; Claessen SM; van Nederveen FH; Giesen V; Dannenberg H; van der Harst E; Dinjens WN; de Krijger RR
Mod Pathol; 2008 Apr; 21(4):407-13. PubMed ID: 18223555
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers.
Moley JF; Brother MB; Wells SA; Spengler BA; Biedler JL; Brodeur GM
Cancer Res; 1991 Mar; 51(6):1596-9. PubMed ID: 1998949
[TBL] [Abstract][Full Text] [Related]
10. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2.
Mulligan LM; Gardner E; Smith BA; Mathew CG; Ponder BA
Genes Chromosomes Cancer; 1993 Mar; 6(3):166-77. PubMed ID: 7682102
[TBL] [Abstract][Full Text] [Related]
11. Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET.
Cho NH; Lee HW; Lim SY; Kang S; Jung WY; Park CS
Pathology; 2005 Feb; 37(1):10-3. PubMed ID: 15875728
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity on the long arm of chromosome 22 in pheochromocytoma.
Tanaka N; Nishisho I; Yamamoto M; Miya A; Shin E; Karakawa K; Fujita S; Kobayashi T; Rouleau GA; Mori T
Genes Chromosomes Cancer; 1992 Nov; 5(4):399-403. PubMed ID: 1283329
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma.
Nelkin BD; Nakamura Y; White RW; de Bustros AC; Herman J; Wells SA; Baylin SB
Cancer Res; 1989 Aug; 49(15):4114-9. PubMed ID: 2568166
[TBL] [Abstract][Full Text] [Related]
15. The RET proto-oncogene and cancer.
Donis-Keller H
J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
17. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes.
Moley JF; Brother MB; Fong CT; White PS; Baylin SB; Nelkin B; Wells SA; Brodeur GM
Cancer Res; 1992 Feb; 52(4):770-4. PubMed ID: 1346584
[TBL] [Abstract][Full Text] [Related]
18. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
Komminoth P; Roth J; Muletta-Feurer S; Saremaslani P; Seelentag WK; Heitz PU
J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
[TBL] [Abstract][Full Text] [Related]
19. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
20. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
Eng C; Foster KA; Healey CS; Houghton C; Gayther SA; Mulligan LM; Ponder BA
Br J Cancer; 1996 Aug; 74(3):339-41. PubMed ID: 8695346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
